White House signs executive order to expand access to psychedelic therapies

President Trump signed an executive order aimed at increasing the availability of psychedelic drug treatments. The order was announced alongside podcaster Joe Rogan, who said he had messaged the president about research on ibogaine.

In a STATus Report interview, host Alex Hogan and Washington correspondent Daniel Payne discussed what the order actually entails and its limitations. They noted that the policy signals a shift toward greater acceptance of psychedelics for difficult-to-treat conditions.

The conversation highlighted growing interest in using psychedelics such as ibogaine to address addiction, depression and PTSD, reflecting broader momentum in the mental-health and pharmaceutical fields.

The executive action does not constitute a full approval of any specific drug, but it may pave the way for expanded research and potential future approvals.